Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
about
Hypersensitivity Responses in the Central Nervous SystemAquaporin-4 autoimmunityAtypical presentations of neuromyelitis opticaChallenges and opportunities in designing clinical trials for neuromyelitis opticaMolecular pathogenesis of neuromyelitis opticaIs Multiple Sclerosis an Autoimmune Disease?Biomarkers in Multiple Sclerosis: An Up-to-Date OverviewFulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathologyPathology of multiple sclerosis: where do we stand?Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.Update on neuromyelitis optica: natural history and management.The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritisCerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaThe pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.Central role of glia in disease researchUpdate on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis opticaBody fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureConsensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.The growing spectrum of antibody-associated inflammatory brain diseases in children.New insights into neuromyelitis opticaImmune mediated diseases and immune modulation in the neurocritical care unitAstrocytes are an early target in osmotic demyelination syndromeCerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier.AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Neuromyelitis optica: an often forgotten cause of intractable nausea and vomiting.Horner Syndrome in a Case of Neuromyelitis Optica.CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditionsCSF biomarkers in neurodegenerative diseases.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.
P2860
Q26779177-0BA79CCD-6440-41B3-BDEB-EE9B46FC5AC5Q26799559-6A0BC1C2-5766-4329-AF82-1FAB944DDA88Q26827156-2FB12C67-4060-4F5D-9842-0BC54AB171EEQ26999708-B97740EA-9F01-4527-A880-C9796603378EQ27021535-CB847AE3-E5D9-4107-B0BF-6B04CC2FC558Q27496011-1DF0E93C-4566-41E8-8A5C-B66EB0E5FFC7Q27496017-CD2EC58C-46AE-4BA5-A334-617B0785B1BAQ28270042-BC639403-72BA-44F7-882E-F07A61AA22A0Q28296052-043ABFD9-5C83-425F-AFC1-6F1148424C19Q30577078-CD4E9D5A-7D64-48CF-8684-FEB9D30AEFC5Q30676331-757CC612-8F61-4739-9CEE-B333FD5715A2Q30833332-4F99CB08-BFC5-45FE-909E-AA23D3687B46Q30975717-C2B73E34-666B-4108-BD49-F5E42B69A098Q33592132-E100338F-4B45-40A8-BE1C-59562104BF60Q33702126-2BEC9B86-D2A6-4E62-82A3-5141131F288EQ34005484-A4E0A20F-D067-410C-985C-51FAD74F8C2DQ34235490-6DAF89F0-C43B-40AF-B858-3B6F90C3151CQ34338762-825A310A-548A-49C7-B124-0AD19E2D24A0Q34392387-4F1BB371-0A23-4152-ADD4-21DDAD69A287Q34440538-2B617C8C-3F2D-4075-95C6-EFBD442FF706Q34726977-6991E7D0-7C80-4D70-AD0F-0D58AF6A4192Q35052199-1421D4FB-49F6-44E4-A80C-654FC24EE157Q35067939-4995F080-5746-4A92-9AB6-A21DEA171192Q35078327-00FE055C-4896-44BC-BDCB-ED5BAFC0772CQ35377133-D84B5B45-B314-4345-96B8-0189FA268889Q35441181-E4119FBE-0F6C-458E-870E-2AD460C618FAQ35539641-5C45D0DC-20A2-4CB0-B166-8EB047F1A5BEQ35729575-2F1BACDA-06FC-4FA9-9AB8-49818592F58BQ36001661-C95EC1C3-CB91-4889-A2C3-FAE588AA7D68Q36010441-C56474DA-757E-4E80-A6F4-19EC0CE4B9E1Q36293971-9D905F64-6FCF-4F91-BBF3-CA5DC3270BDEQ36303835-88DAFFC8-5E4C-4BD8-BC33-74F974FD9369Q36348690-4456F12E-2234-4CE9-9081-FFA3D3E9AA8BQ36500261-72BFCFB5-9D9D-43C4-8EAF-9BA853005B76Q36547012-4B8AC23C-5B21-49EC-BECD-DBC8B8AEB443Q37057962-B328FA0D-61DE-4235-AB19-842FDD1F7F18Q37439288-B855EA1D-5067-4ECD-87B7-6108C680B7A5Q37646434-8AEE553B-D4E6-4FBF-B597-E65240C3669EQ37837903-9EA4073F-FC87-4AF9-A0DD-1E046FF7ADC1Q38088747-45C5915F-99A3-4092-B406-EA8B76C49374
P2860
Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Astrocytic damage is far more ...... clinical CSF biomarker study.
@en
Astrocytic damage is far more ...... clinical CSF biomarker study.
@nl
type
label
Astrocytic damage is far more ...... clinical CSF biomarker study.
@en
Astrocytic damage is far more ...... clinical CSF biomarker study.
@nl
prefLabel
Astrocytic damage is far more ...... clinical CSF biomarker study.
@en
Astrocytic damage is far more ...... clinical CSF biomarker study.
@nl
P2093
P1433
P1476
Astrocytic damage is far more ...... clinical CSF biomarker study.
@en
P2093
P304
P356
10.1212/WNL.0B013E3181E2414B
P407
P577
2010-07-01T00:00:00Z